2026 POSTER PRESENTATIONS
Poster Awards will be announced Tuesday at 2:00pm and Wednesday at 7:00pm
POSTER SESSION A: Monday – Tuesday morning
A001: Digital Membrane Chromatography — A New Way to Rapid Antibody Purification for Top-Down Mass Spectrometry, Presented by Ken R., i3 Membrane Corporation
A002: Binding Kinetics Measured on Cells – Pain or Gain?, Presented by Vera M., 2bind
A003: Metabolic Class B GPCR Agonist Antibodies Discovered by Library-Scale Functional Selection, Presented by Jose Carlos PR., Abalone Bio
A004: VHH Discovery Beyond B Cells - Antibody Discovery from Serum Using Machine Learning Models for In Silico Selection, Presented by Natalie C., Abterra Biosciences, Inc.
A005: Utilizing Fully Human Long CDR3 Transgenic Mice for Antibody Discovery Against Recessed Epitopes and Challenging Targets, Presented by Andra L., AbTherx
A006: Leveraging Fully Human Long CDRH3 and Common Light Chain Transgenic Technologies for GPCRs and Complex Modalities, Presented by Abhishek S., AbTherx
A007: Harnessing the Adimab Platform for the Discovery of TTX-080: A Clinical HLA-G Antibody, Presented by Rohan K., Adimab LLC
A008: AI-Ready by Design: Data Integration Improves Adimab's Antibody Discovery and Engineering Platform, Presented by Bingjie O., Adimab LLC
A009: Generating Potent and Specific Soluble TCR-Based T Cell Engagers via a High-Throughput Yeast-Based Platform, Presented by Mrunal S., Adimab LLC
A010: PURExpress® Enables High Throughput, Cell-Free Synthesis of De Novo Miniprotein Binders and SPR Dissociation Rate Ranking, Presented by James B., AI Proteins
A011: Corynex®: Scalable Secretion Service for Long-Chain Peptides Including GLP-1-Related Peptides, Presented by Makoto K., Ajinomoto Co., Inc.
A012: Development of Major Histocompatibility Complex Class II Scaffolds for the Selective Modulation of Antigen-Specific CD4 T Cells, Presented by Alexis C., Albert Einstein College of Medicine
A013: Development of Innate Immune Cell Redirectors for the Depletion of Antigen Specific Autoreactive T Cells, Presented by Kevin T., Albert Einstein College of Medicine
A014: Anchored Fully Humanized Monoclonal Antibodies for Cancer Treatment, Presented by Sailaja B., Ankyra Therapeutics
A015: Comprehensive Discovery Biology Solutions in Cell and Protein Sciences for Accelerating Your Drug Discovery Programs, Presented by Srivats R., Aragen Life Sciences
A016: Immunology Innovation Program: Developing Antibodies Against Novel Targets via Co-Creation, Presented by Søren C., argenx BVBA
A017: A Rapid, SPE-free N-Glycan Profiling Workflow for High-Throughput Analysis of Complex Biologics, Presented by Ao L., Asimov, Inc.
A018: A Seamless In Silico-to-Expression Pipeline: Ultra-Rapid Antibody Generation and Analytics, Presented by Sridhar G., ATUM
A019: ActRIIA/ActRIIB Dual Antagonist mAb Drives Weight Loss While Preserving Lean Muscle, Presented by Vishal K., Aureka Biotechnologies
A020: Closed-Loop High-Throughput Biology and AI for Functional Antibody Discovery, Presented by Alon W., Aureka Biotechnologies
A021: Advancing VHH Discovery Leveraging a High Throughput B Cell-Based Platform to Maximize Diversity and Target Specificity, Presented by Ilse R., AVS Bio
A022: CRB2104: A 2:1 AMHR2/CD3 T Cell Engager Targeting AMHR2-Positive Solid Tumors, Presented by Guan W., Biocytogen
A023: Data-Driven Developability Assessment of Antibody Candidates Using High-Throughput Biophysical Assays, Presented by Haoming Z., Biointron
A024: Rapid Generation of Bispecific Antibodies for High Throughput Screening with SpyLock Technology, Presented by Miao L., Bio-Rad Laboratories, Inc.
A025: miniCARbids - A Novel Engineering Platform for Small, Human-Derived Binding Domains Tailored for Car T Cell Therapy, Presented by Julia M., BOKU - University of Natural Resources and Life Sciences
A026: RABIT: Rapid Automated Binder Identification Technology, Presented by Alex B., Broad Institute of MIT and Harvard
A027: Integrated Biophysical Analysis of Fc–FcR Binding, Affinity, and Avidity in Antibody Therapeutics, Presented by Rafael L., Bruker Biosensors
A028: Characterizing Challenging Membrane Targets Using HT-SPR, Presented by Josh E., Carterra, Inc.
A029: Instant Large-Scale Electroporation for Fast Expression of Antibodies in CHO Cells and HEK293 Cells, Presented by Jian C., Celetrix LLC
A030: New Approach Methodologies (NAMs): Retrogenix® Technology for Rapid Early-Stage High-Throughput Screening and Toxicology Species Selection, Presented by Laura R., Charles River Laboratories
A031: 3dpredict/Ab - High Throughput Antibody Structure and Ensemble Protein Property Predictions, Presented by Alain A., Chemical Computing Group
A032: A Function-First ML-Guided High Throughput Screening Platform for the Discovery of VHH-Based T-Cell Engagers, Presented by Edward K., Coding Bio
A033: Multi-Pass Complex Proteins Displayed on Virus-Like Particles Are Bioactive in Binding to Specific Antibodies and Ligands, Presented by Shixia W., Conigen Bioscience
A034: Accelerating Biosimilars Development with Biacore™ Sensorgram Comparison, Presented by Kristi R., Cytiva
A035: Epitope Mapping Case Studies by Deep Mutational Scanning, Presented by Fabien Q., Deeptope
A036: Tensor: Functional Screening of 13,000 T Cell Engagers in 3D Tumor Organoids to Engineer Trispecific Antibodies with AND-Gated Anti-Tumor Activity, Presented by Emma W., Digital Biology, Inc.
A037: Engineering Bispecific VHHs as Biased IL-10 Receptor Agonists for Inflammatory Bowel Disease, Presented by Sherry L., Eli Lilly and Company
A038: AI-Assisted Data Exploration in Bioinformatics Platforms for Early Drug Discovery, Presented by Piotr V., ENPICOM B.V.
A039: Engineering VHH Fusion Antibodies Targeting a Key Driver of Liver Metastasis Formation in Colorectal Cancer, Presented by Karolin B., ETH Zurich
A040: AI-Assisted Antibody Discovery: Integrating Codon Optimization, Single B Cell Screening, and Computational Humanization, Presented by Chuanting T., Eton Bioscience, Inc.
A041: EXPLORER Platform: Fast-Track of Potent and Developable Antibodies to IND, Presented by João S., FairJourney Biologics
A042: Driving Antibody Optimization with Broad-Space and Structure Guided Platforms: Tumbler™ and Targeted Engineering, Presented by Kathrin Z., FairJourney Biologics
A043: FPE024,a CD19/BCMA Dual-targeting VHH Format T-Cell Engager with Novel CD3 Binder for Enhanced Potency and Safety Profile, Presented by Max W., Fapon Biopharma
A044: Characterising Multivalent Complex Formation Using Controlled Complex Lifetime with FIDA, Presented by Travis M., Fidabio
A045: Detection of Antibody-Secreting Cells in Cyto-Mine® Chroma: Comparison of Two Bead-Based and One FRET Antigen-Specific Assays, Presented by Caroline F., Fluidic Sciences Ltd.
A046: Cross-Reactivity and Selectivity Comparisons Between Immune-Derived and Discovery Libraries from the AbNano Platform, Presented by Sam S., Fortis Life Sciences
A047: OptiMAL®: Mammalian Display for Antibody Discovery, Presented by Pedro C., Fusion Antibodies plc
A048: The Evolution of Antibody Screening: Automation-Integrated BLI for Next-Generation Discovery Workflows, Presented by Benjamin O., Gator Bio
A049: High Throughput Mass Spectrometry Analytics for ML/AI Ready Drug Discovery, Presented by Annie G., Genedata AG
A050: Harmonizing and Streamlining Chromatography and Electrophoresis Data Workflows with Genedata Chromatics, Presented by Alyssa L., Genedata AG
A051: A Strategy to Produce a "Self-Destructive" Enzyme by Harnessing Its Activity Profile, Presented by Swapnil G., Genentech
A052: Development of Fully Human Anti-CD71 Monoclonal Antibodies with Blood-Brain Barrier Penetration Using the SmocMab Platform, Presented by Dongxiao F., GenoBioTX
A053: Dynamics of Immune Activation and Killing Induced by HBV T Cell Engagers, Presented by Pawan K., Gilead Sciences
A054: A Therapeutic Nanobody Targeting ENPP1 Reveals Tumor Control and Engages the Nuclease-Like Domain, Presented by Angelo N., H. Lee Moffitt Cancer Center & Research Institute
A055: Engineering and Manufacturing of Complex Biologics: AI-Guided Optimization of Multispecific Antibodies, Presented by Mart U., Icosagen Cell Factory OÜ
A056: Comprehensive Profiling of HLA Class II Immunopeptidomes to Discover Targets for Autoimmune Diseases, Presented by Heiko S., Immatics Biotechnologies GmbH
A057: Library vs Library Selection Platform for Discovery of Epitope Specific Antibodies, Presented by Swethika B., Institute for Protein Innovation
A058: Discovery of Developable VHHs from a Humanized Synthetic Yeast Display Library, Presented by Deepash K., Institute for Protein Innovation
A059: Antibody Reagents to Validate Impossible Protein Targets, Presented by Ross C., Integral Molecular
A060: A New Approach Methodology (NAM) for Specificity Testing, Presented by Rachel F., Integral Molecular
A061: From High-Quality mAb Discovery to Multispecific Therapeutics: Discovered. Designed. Delivered, Presented by Bonnie H., Invenra
A062: End to End Protein Science Solutions Enabling Translational Research and Clinical Assays, Presented by Vitalie S., IQVIA Laboratories
A063: NSGF6T, a Humanized Mouse Model Recapitulating Key Features of Psoriasis for Translational Research, Presented by Nijaguna B., Jackson Laboratory
A064: A New and Differentiated Transgenic Platform for Rapid Generation of Developable Human Therapeutic Antibodies, Presented by Kit F., Jackson Laboratory
A065: Biofloating: A Cell-Based Workflow for the Discovery of Antibodies Targeting Multi-Pass Transmembrane Proteins, Presented by Justyn F., Johns Hopkins University
A066: Design of a Suspension-Based Mammalian Cell Interaction Platform for Antibody Discovery, Presented by Pilar O., Johns Hopkins University
A067: Engineering a Novel Interleukin-2-Based Immunocytokine with Enhanced Effector and Memory Function, Presented by Anjali S., Johns Hopkins University
A068: Recombinant Kallikrein (KLK) Family Proteins, Presented by Jordan C., KACTUS
A069: The Native Edge: KACTUS CD3 VLPs and Nanodiscs for Precision T-Cell Therapy and Discovery, Presented by Jia C., KACTUS
A070: GMP VHH Platform for Rapid Tox and Clinical Access, Presented by Junya A., Kaneka Eurogentec SA Biologics
A071: MPSA-AB5000: A High-throughput Membrane Proteins Screening Array for Therapeutic Biologics Specificity Profiling, Presented by Hang C., KYinno Biotechnology (Beijing) Co., Ltd.
A072: Envisia: Advancing Antibody Discovery with Function-Focused Profiling at the Single-Cell Level, Presented by Simon M., Lightcast Discovery Ltd.
A073: One Platform, Four Applications: Multiplexed Focal Molography for DEL Hit Validation, PROTAC Linker Design, Plasma Protein Binding, and Fc Receptor Profiling, Presented by Lukas H., lino Biotech AG - A Miltenyi Biotec Company
A074: Accelerating Therapeutic Antibody Discovery with High-Throughput Droplet Microfluidics, Presented by Ellen B., Live Drop
A075: A Proteotranscriptomic Approach to Generate Monoclonal Antibodies by LC-MS/MS and Single Cell BCR Sequencing, Presented by Miriam D., Miltenyi Biotec B.V. & Co. KG
A076: Generic Computational AI Based Engine for Protein Expression Optimization: A Standardized Engineering Framework for Global Biomanufacturing, Presented by Eran M., MNDL Bio
A077: Quest for Mucin-4 Glycopeptide Specific Antibodies as Potential Anti-Cancer Immunotherapies, Presented by Achyut D., National Institutes of Health, National Cancer Institute
A078: Discovery of Camel VHH and Shark VNAR Nanobodies by Phage Display for Developing Cancer Therapeutics, Presented by Jessica H., National Institutes of Health, National Cancer Institute
A079: Cold-Active TEV Protease: Engineered for Higher Performance at Low Temperatures, Presented by Carine RI., New England Biolabs, Inc.
A080: Development of a Nanobody Producibility Model Using High-Throughput Cell-Free Expression and Purification, Presented by Alena R., Ordaos Bio
A081: Harnessing the Best of Both Worlds: GT-008, a Versatile Tumor-Selective Anti-CD24 Antibody for Radiotheranostic and ADC Strategies, Presented by Andreas F., Pentixapharm AG
A082: Multi Attribute Monitoring and Comprehensive Analysis of mAb CQAs Throughout the Manufacturing Process, Presented by John A., Pharmaron
A083: Preclinical Development of a VHH-ADC Using the Pfenex Platform, Presented by Russell C., Primrose Bio
A084: Unlocking Rapid, Scalable Lentiviral Vector Production with Stable Pools, Presented by Anneliese K., ProBioGen AG
A085: Overcoming Limitations of Constitutive Protein Expression with the Power of Optogenetics, Presented by Kiana MS., Prolific Machines
A086: New Methods for MOA-Based Potency Testing and CAR-T Cell Characterization, Presented by Julia G., Promega Corporation
A087: Developability of RNDO-564: A Novel CD28 x Nectin-4 Costimulatory bsAb for the Treatment of Solid Tumors, Presented by Katja R., Rondo Therapeutics
A088: Target Density Matters - Binding Kinetics of Antibody-Based Therapeutics Are Highly Influenced by Target Expression Levels, Presented by Holly G., RoukenBio
A089: Towards Nanobody® Thermostability Prediction with In House Sanofi Data, Presented by Pep AR. & Ruijiang L., Sanofi
A090: Streamlining Drug Discovery with High-Throughput Screening by Cytometry, Presented by Jonah R., Sartorius
A091: From DNA Template to BLI Kinetics in a Day - Using Octet® VHH Biosensors to Directly Analyze VHHs Produced in NEBExpress® and PURExpress® Cell-Free Protein Synthesis Systems, Presented by Gregory W., Sartorius
A092: Discovery of a Novel IgM Cleaving Protease to Treat Autoimmune Diseases, Presented by Colin L., Seismic Therapeutic
A093: Yeast Display for Protease Engineering and Activity Screening, Presented by Samuel P., Seismic Therapeutic
A094: End-to-End Solutions for Protein Biologics: From Target Selection to Drug Delivery, Presented by Edyta Z., Selvita S.A.
A095: Precision Fc Engineering via Glycosylation-Competent CHO Display Enables Selective Fc?RIIIa Targeting and Enhanced Antitumor Activity, Presented by Migyeong J., Seoul National University
A096: Stealth-Body: A Next-Generation IgG Fc Variant with Complete Effector Silencing and Preserved Developability, Presented by Suyeon K., Seoul National University
A097: Engineered B7-H6 Enhances NKp30-Mediated NK Cell Activation in Bispecific Engagers, Presented by Bomi K., Seoul National University
A098: Discovery and Characterization of a Human and NHP Cross-Reactive Anti-CD3 Nanobody, Presented by Teddy Y., Shanghai Hongcheng Pharmaceutical Co. Ltd.
A099: Decoding Local Interactions of Novel Excipients with Antibodies for Viscosity Prediction in High-Concentration mAb Formulations via Molecular Dynamics, Presented by Dariya B., Stevens Institute of Technology
A100: Application of Clinical Stage GlycoConnect® Technology to Bispecific Antibodies Yields Improved Bispecific ADCs in Comparison to Randomly Conjugated bsADCs, Presented by Aron M., Synaffix BV
A101: GlycoConnect® ADC Toolbox Expansion with Dual Payload ADC (dpADC) Technology, Presented by Remon V., Synaffix BV
A102: Pooled Binder Screening for Accelerated CAR gdT Discovery, Presented by David B., Takeda Pharmaceuticals
A103: Optimizing Antibody Affinity and Biophysical Properties Using Yeast Display, Presented by Laura D. & Satyendra K., Takeda Pharmaceuticals
A104: Scalable, Automated Monoclonal Antibody Purification: High-Recovery Workflows via AffinEx™ Protein A SPE Cartridges on Resolvex® Positive Pressure Systems, Presented by Qi H., Tecan Group Ltd.
A105: Discovery of Epitope-Defined Oncology Targets to Enable High Therapeutic Index ADCs, Presented by Daniel M., TenSixty Bio
A106: De-Risking Antibody Development Early: Combining High-Yield Expression with Deep Developability Profiling, Presented by Philipp C., Thermo Fisher Scientific
A107: Expi293™ PRO Expression System: Improved Expression Across a Broad Range of Proteins, Product Quality Assessments and Purification Compatibility, Presented by Jonathan Z., Thermo Fisher Scientific
A108: Universal Rapid Clear® 24-Well Filter Plate (7mL); A 5-Minute Spin for Clarification Solution for all Molecule Types, Presented by Meet P., Thomson Instrument Company
A109: Antibody Discovery from Immune VHH Library Using Yeast Surface Display, Presented by Steven T., Twist Bioscience
A110: Rapid Discovery of Hundreds of Rabbit mAbs with High Affinity and Cell Binding Against CD19 Utilizing the Beacon Optofluidic Platform, Presented by Lynette T., Twist Bioscience
A111: Using CombiCells to Measure Antigen Sensitivity of T Cell Engagers, Presented by Katerina K., University of Oxford
A112: Autoantibody-Based Antibody-Drug Conjugates as Personalized Cancer Therapy, Presented by Shruthi M., University of Pennsylvania
A113: Leveraging the Tumor Microenvironment for Conditional Antibody-Drug Conjugate Activation, Presented by McKenna F., University of Texas, Austin
A114: Taming the Beast: A Discovery Pipeline for Multimeric Nanobody-Fc Therapeutics Targeting Pseudomonas aeruginosa, Presented by Kelli H., University of Texas, Austin
A115: Functional Flexibilities and Constraints of VRC01 Lineage HIV Broadly Neutralizing Antibodies Revealed by Deep Mutational Scanning, Presented by Jamin W., University of Utah
A116: Structural Clarity for Biologics: High-Resolution Protein Characterization Services from Baselayer Biosciences, Presented by Charles M., University of Washington
A117: Antibody Discovery for Complex Membrane Antigens, Presented by Ernest S., Vaccinex
A118: Rapid Purification of IgG Samples in Novel 96-Well Dialyzer with External Reservoir, Presented by Bob T., Vivaproducts, Inc.
A119: High-Throughput Mapping of Hemagglutinin pH Stability Using Yeast Display and Deep Mutational Scanning, Presented by Qingfa H., Washington University in Saint Louis
A120: Luedeking-Piret Regression for Multi-Step-Ahead Forecasting and Clone Selection in Monoclonal Antibodies Biomanufacturing, Presented by Brian B., Wheeler Bio
A121: Translational In Vivo Characterization Platform for T Cell Engagers via NHP and hFcRn Mice, Presented by Sujata N., WuXi Biologics
A122: CrossBody: A Variable Region Domain-Splitting Multispecific Antibody Architecture Enabling Tumor-Selective Target Engagement for Precision Immunotherapy, Presented by Xiaoyan L., XTOP Biotherapeutic, Inc.
A123: Single B Cell Platform Enables TCR-Mimic Rabbit Antibodies Against EGFR Neoantigen, Presented by Dong H., Yurogen Biosystems LLC
A124: Development of a Humanized Anti-CDH3 Antibody Using a Single-Cell Strategy for Diseases with Aberrant CDH3 Expression, Presented by Yang L., Yurogen Biosystems LLC
POSTER SESSION B: Tuesday afternoon – Wednesday
B001: Electrochemical Elution Reduces Aggregation of pH-Sensitive Monoclonal Antibodies in Digital Membrane Chromatography, Presented by Jane J., i3 Membrane Corporation
B002: The Format Matters: Stabilities of Bispecifics, Presented by Anna-Lena H., 2bind
B003: ORIGIN-1: An Experimentally Validated Generative AI Platform for De Novo Antibody Design Against Zero-Prior Epitopes, Presented by David S., Absci Corp
B004: GRIFFIN: A Mass Spectrometry-Based Method for Polyclonal Antibody Sequencing Directly from Protein, Presented by Stefano B,, Abterra Biosciences, Inc.
B005: Anti-CD3 Heavy Chain-Only Antibody (HCAb) Panel for Use in T-Cell Engaging Therapeutics, Presented by Hannah W., Adimab LLC
B006: Accurate mAb Sizing by CE-SDS Using the NIST mAb as a Ladder for the Agilent ProteoAnalyzer System, Presented by Kyle L., Agilent Technologies
B007: Corynex® for Next-Generation VHHs: Site-Specific Conjugation via ncAA Incorporation and Half-Life Extension via PASylation®, Presented by Yumi N., Ajinomoto Co., Inc.
B008: PASylation® in Enzyme Engineering: Impact on Biophysical Properties, In Vivo Half-Life and Catalytic Activity, Presented by Uli B., XL-protein GmbH
B009: Accelerating Single-Domain Antibody Discovery and Optimization via Mammalian Cell–Based Directed Evolution and AI/ML-Guide Digital Design, Presented by Charlotte P., Alloy Therapeutics
B010: Unlocking the Full Potential of Rabbit Monoclonal Antibodies with Cellestive™, Presented by Joshua L., Antibody Solutions
B011: Mapping Formulation-Dependent Protein Behavior with the Liquid Brain, Presented by Jack H., Apoha
B012: From B Cell to Sequence in Days: Optofluidic Platform Powers Antibody Identification Across Indications, Presented by Pavlo G., AstraZeneca
B013: A Novel Bispecific Approach to Eliminate Light Chain Mispairing, Presented by Joe B., ATUM
B014: Novel Blood-Brain Barrier Penetrating Heavy Chain-Only Antibodies Targeting CD98, Presented by Benny Y., Biocytogen
B015: AbDrop™ Speeds: Accelerating Your Antibody Discovery with Single B Solution, Presented by Mia D., Biointron
B016: Peptide Mapping, Perfected: In-House LC-MS from NIST Standards to Complex Biotherapeutics, Presented by Joseph C., Bionova Scientific
B017: Challenges and Opportunities in Targeting Peptide-HLAs with Antibody Therapeutics for Oncology, Presented by Nicole D., Boehringer Ingelheim Pharmaceuticals, Inc.
B018: Discovery to Development: Computational Approaches for Immunogenicity De-Risking, Presented by Kyle M., Boehringer Ingelheim Pharmaceuticals, Inc.
B019: Advanced Tools for Bispecific Antibody Generation and Validation, Presented by Michelle K., BPS Bioscience, Inc.
B020: SpySPR: Rapid High-Throughput SPR Characterization for Nanobody Discovery Using Unpurified VHH from IVTT Reaction, Presented by David D., Broad Institute of MIT and Harvard
B021: Automation of Ribosome Display for High Throughput Binder Selection, Presented by Alexandra V., Broad Institute of MIT and Harvard
B022: Function-First Single-Cell Discovery and Characterization of Bispecific T Cell Engagers, Presented by Vincent P., Bruker Cellular Analysis
B023: Strategies for Scalable and Sensitive Determination of High Affinity and Slow Dissociating Binding Interaction Kinetics in Antibody Discovery, Presented by Christine N., Carterra, Inc.
B024: Automated Antibody Discovery and Screening Using CellRaft® Technology, Presented by Jessica H., Cell Microsystems
B025: Prediction of Immunogenicity and Vaccine Effectiveness Using Viral Genomic Variation, Presented by Liz C., Chinese University of Hong Kong
B026: Engineering Dendritic Cell-Targeting Nanobodies for Antigen Delivery, Presented by Max K., Columbia University
B027: A Panel of Class A, B and F GPCR-Specific Antibodies Can Detect the Targets Expressed on Live Cell Surfaces by Flow Cytometry, Presented by Jean Q., Conigen Bioscience
B028: From Copolymer Screening to Plug-and-Play Purification: Automated NativeMP™ Platforms for Membrane Proteins, Presented by Michael R., Cube Biotech GmbH
B029: Antibody Optimization Case Studies by Deep Mutational Scanning, Presented by Charlotte P., Deeptope
B030: LYSward™ : An Engineering Platform to Generate a pH-Dependent Antibody for Antibody Drug Conjugate, Presented by Shih-Chong T., Development Center for Biotechnology
B031: RamaX: A Platform for Ultra-Rapid Binder Screening, Discovery, and Optimization, Presented by Namrata A., Diffuse Bio, Inc.
B032: Unlocking Agonism: A Comprehensive Strategy to Characterize Agonistic Antibodies for Immunotherapy & Autoimmunity, Presented by Jennifer LJ., Eurofins DiscoverX
B033: Accelerating Drug Discovery: De-Risking Complex Multi-Specific and Multi-Format Biologics with a CMC-Predictive Mammalian Display Platform, Presented by Manon F., FairJourney Biologics
B034: Dissecting Human and Cynomolgus FcRn Interactions to Drive Antibody Half-Life Design and Fast Track Development, Presented by Silvestre L., FairJourney Biologics
B035: Clone Selection from Un-Purified Samples, Presented by Travis M., Fidabio
B036: Machine Learning Guided Interaction Analysis, Presented by James W., Fluidic Sciences Ltd.
B037: Molecule-Specific Compatibility of Bispecific Scaffolds: The Necessity of Multi-Format Empirical Testing for Novel Fab Pairs, Presented by Christopher B., Food Allergy Science Initiative (FASI)
B038: Rapid and High-Throughput SPR Characterization of VHH Discovery Leads Across Related Polymerase Targets for LAMP Dx, Presented by Sam S. & Engin Y., Fortis Life Sciences & SPOC Biosciences
B039: A Rational Affinity Maturation Platform - RAMP, Presented by Richard M., Fusion Antibodies plc
B040: AI-Engineered NovoBody™-Based Probe for “High Capacity, Low Drift” BLI Analysis of His-Tagged Proteins, Presented by Benjamin O., Gator Bio
B041: Surface-Aware Deep Learning for Prediction of Protein Hydration Thermodynamics from Conformationally Diverse Structures Using GIST Labels, Presented by Naryeong K., Genentech
B042: A Next-Generation Transient CHO Expression Platform Accelerating Antibody Discovery from Screening Service to In-House Production, Presented by YC L., GenScript
B043: PROPHET-Ab: An Automated Platform for High-Throughput Antibody Production and Developability Characterization, Presented by Ammar A. & Josh M., Ginkgo Bioworks
B044: Reagents for High-Yield, Automation-Friendly Protein Expression: Cell Free Protein Synthesis Kits and Engineered Pichia pastoris, Presented by Monica M., Ginkgo Bioworks
B045: Tumor-Restricted Tn- MUC1 Glycoepitopes Enable Precision ADC Therapy with Robust Efficacy and Favorable Safety, Presented by Nisha S., GO Therapeutics
B046: Enhancing Solubility and Expression of a Binder Through Targeted Linker Engineering, Presented by Heather R., GSK
B047: Unlocking Tumor Access: Targeting COL6A3 on the Stroma of Solid Tumors with a TCR-Based Bispecific, Presented by Nadine A., Immatics Biotechnologies GmbH
B048: Extending MAPPs-Based Immunogenicity Risk Assessment to Therapeutic Peptides and Antibody–Drug Conjugates, Presented by Elise P., ImmuneSpec
B049: Multimodal Fusion of Empirical Structural Data and Deep Learning for Improved Modeling of Antibody–Antigen Complexes, Presented by Daniel B., Immuto Scientific
B050: A Systematic Evaluation of Fusion Tags and Chaperone Proteins To Improve Antigen Solubility and Yield, Presented by Fabbiha H. & Karunya R., Institute for Protein Innovation
B051: A Non-Profit Institute’s Community Based Approach to Make Highly Validated Recombinant Antibodies for Scientific Research, Presented by Nilisha M., Institute for Protein Innovation
B052: CDR-Scanning for Antibody Engineering and New IP, Presented by Ben D., Integral Molecular
B053: Diverse Library Generation using IDT oPools and Synthetic Biology Custom Solutions, Presented by Jordan K., Integrated DNA Technologies
B054: New Approach Methodologies for Risk Assessment and Functional Evaluation of Drug Candidates, Presented by Sofie P., IQVIA Laboratories
B055: Rapid and Robust Evaluation of Higher Order Structural Differences in Bispecific Antibodies by Circular Dichroism Spectroscopy, Presented by Forrest EK., Jasco, Inc.
B056: Engineering Antibody-Invertase Fusion Proteins for Quantitative Detection of Infectious Disease-Specific Antibodies Using Commercial Glucometers, Presented by Xinran A., Johns Hopkins University
B057: Engineered CD19-Targeting Interleukin-21 Mimetic to Study and Manipulate B-Cell Biology, Presented by Nikol GE., Johns Hopkins University
B058: Engineering a High Affinity SARAH Domain for Hippo Signaling Inhibition, Presented by Kaitlin J., Johns Hopkins University
B059: Engineering Interleukin-4-Based Antibodies Fusion Proteins for Targeted Immune Modulation, Presented by Sonya KB., Johns Hopkins University
B060: Transforming Tumor Research: Engineering MHCs as Versatile Reagents, Presented by Maggie G., KACTUS
B061: K-Neuro: An SPR-Based Platform for Accelerating Drug Discovery in Neurodegenerative Diseases, Presented by Nicolas H., Kimialys
B062: Kuhner TOM for Off-Gas Analysis in Shake Flasks, Presented by Michael K., Kuhner Shaker, Inc.
B063: Development of Cis-Binding Biparatopic Antibodies as TNFR2 Antagonists, Presented by Hiroki A., Kyoto University
B064: From AI Designs to Oncology Leads in Days: Bridging the Lab-in-the-Loop Gap with ALiCE®, Presented by Jonathan F., LenioBio GmbH
B065: From iPSCs to Immune Cells: High-Throughput Production and Single-Cell Functional Analysis with Droplet Microfluidics, Presented by Stéphanie V., Live Drop
B066: Avidion: High-Throughput Cell Binding Avidity Platform for Screening Cell Engagers, Multispecific Antibodies, and Cell Therapies, Presented by Riley P., LUMICKS
B067: Enabling High-Throughput CE-SDS and Peptide Mapping Through Automated Characterization Workflows on the Hamilton STARlet, Presented by Ariel K., Merck Research Laboratories
B068: Multi-Specific Molecule Discovery with the Metaphore Knowledge Base, Presented by Brian F., Metaphore Biotechnologies
B069: Optimizing Biologics Developability Assessment: A Multi-Parameter Approach With Thermal and Colloidal Stability Measurements for Improved Candidate Selection, Presented by Ping Z., NanoTemper Technologies
B070: Engineering Nanobody-Peptide Conjugates to Dissect GPCR Function in Diabetes and Obesity, Presented by Phoenix D., National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
B071: The Versatility of Cell-Free Protein Expression Systems: Comparative Study Across Conditions and Platforms, Presented by Paula M., New England Biolabs, Inc.
B072: De Novo Fully Human VH Antibody Discovery Enabled by Nona Biosciences' Hu-mAtrIx™ AI Platform, Presented by Musheng B., Nona Biosciences
B073: Expanding the High-Throughput Protein Stability Toolkit with cDNA Display Pulse Proteolysis, Presented by Ted L., Northwestern University
B074: From DNA to Active, Monomeric β1AR Receptor in <72 Hours, Using Cell-Free Synthesis, Presented by Audrey D., Nuclera
B075: Rapid Cell-Free Triage Screening of an AI-Generated Antibody Library, Presented by Shristi G., Nuclera
B076: Compatibility of the OPM-293 Transient Expression Platform with Expi293F and Expi293 Pro Cells Supports Enhanced Protein Production, Presented by Pargol H., OPM Biosciences, Inc.
B077: pH-Dependent FcRn Binding and Release Assay in a Microplate: A New Method for Screening Fc Interactions of mAbs, Bispecifics and Fc Engineered Antibodies, Presented by Sebastian G., PAIA Biotech GmbH
B078: Establishment of a Patient-Derived Organoid-Immune Cell Co-Culture Platform for Evaluating Immuno-Oncology Therapies, Presented by Mark T., Pharmaron
B079: Single-Cell RNA-Seq Reveals Insights into the Effects of Immune Checkpoint Inhibitors, Presented by Emily W., Pharmaron
B080: The Discovery and Development of a Bispecific T Cell Engager Prodrug Targeting ENPP3 for Renal Cell Carcinoma (RCC), Presented by Yu L., ProBio, a GenScript subsidiary
B081: Ankyrons® - Next Generation Target Binding and Detection, Presented by Olivia W., ProImmune
B082: Binding to Bridging: Complete Suite of FcγR Assay Tools Accelerates Antibody Therapeutic Development, Presented by Kai H., Promega Corporation
B083: FlexAble 2.0 – A Versatile Tool to Label Antibodies with Dyes, Enzymes or Oligos, Presented by Andrea B., Proteintech Germany GmbH
B084: VHHs as Tools for the Analysis of Antibodies and Cytokines Using BLI and SPR, Presented by Christian LW., Proteintech Germany GmbH
B085: Identification of Neoantigen Drug Targets Induced by Tryptophan Depletion, Presented by Reese H., Regeneron Pharmaceuticals
B086: Development of a High-Throughput Multimodal Patient-Derived Platform Integrating Autologous Fibroblasts and Tumour-Infiltrating Lymphocytes for Colorectal Cancer Drug Discovery, Presented by Alison K., RoukenBio
B087: Cell Line Genome Engineering, Presented by Rex L., Royal Veterinary College
B088: From 80 Hours to 2: AI-Powered Curation for Therapeutic Protein Sequence Variant Analysis, Presented by Ian D., Saint Louis University/LiVeritas Biosciences
B089: Two Cell Lines, One Goal: Enabling Reliable Cell-Based Assay Critical Reagent Production, Presented by Bailey AS., Sanofi
B090: How Low Can You Go? High-Sensitivity Kinetics at Low Concentrations with Biolayer Interferometry, Presented by Stuart K., Sartorius
B091: Design and Evaluation of a Dual Mechanism GLP-1R Agonist- Antibody Fusion for Weight Loss with Lean Mass Preservation, Presented by Meghan M., Scholar Rock
B092: Structural Insights into In Vivo Antibody Diversification: How CR3022 Evolves to Target Conserved Epitopes for Pan-Sarbecovirus Neutralization, Presented by Ziqi F., Scripps Research Institute
B093: Engineering and Characterization of an IgE Cleaving Protease, Presented by Soumya B., Seismic Therapeutic
B094: Engineering IL-21 Secretion in T Cells Using Druggable Ligand-Responsive Stabilized Domains, Presented by Seo Jin L., Seoul National University
B095: Advances and Challenges in CAR-T Therapy for Glioblastoma, Presented by Hyeri R., Seoul National University
B096: Cell Mimics Provide Robust Control for T Cell Memory Phenotyping Panels, Presented by Subhanip B., Slingshot Biosciences
B097: Antibody-Guided Cardiac Surgery: Affinity Maturation and Format Optimization of Dye-Conjugated Anti-Contactin-2, Presented by Shivani S., Stanford University
B098: NewPath ADC: A Novel Payload-Focused Approach to Next Generation ADCs, Presented by Joshua G., Sygnature Discovery
B099: Optimizing Plasmid Construct Workflow and Design for Yield and Cloning Efficiency, Presented by Egi H. & Ria B. & Vijay C., Takeda Pharmaceuticals
B100: Rational Design of Antibody Fragments with Lower Off-Target Uptake and Retention at Clearance Organs, Presented by Argin A., Telix Targeting Technologies
B101: Optimization of Membrane Scaffold Proteins (MSPs) for Lipid Nanodiscs Reconstitution Using a PD-10 to Improve Quality and Yield for Biophysical Techniques, Presented by Megan S., Texas Tech University Health Sciences Center
B102: Accelerating Discovery and Rational Engineering of Antibody Modalities Using Cryo-EM, Presented by Tilak G., Thermo Fisher Scientific
B103: A Next-Generation Expi293™ PRO Expression System for Enhanced Protein Expression Yields Across Diverse Protein Classes, Presented by Chao Yan L., Thermo Fisher Scientific
B104: Thomson 7L Flask Replacing Bioreactor and Cell Bags between 5L to 6L/Flask – Ability to Grow up to 35L/Shaker, Presented by Jonas A., Thomson Instrument Company
B105: Comparison of Thomson Optimum Growth® 7L Flasks vs Ambr® 250 Bioreactor Systems Using Stable CHO Cells, Presented by Sam E., Thomson Instrument Company
B106: Doxorubicin-Induced Fibroblast Activation and Pro-Invasive Changes in ECM can be Suppressed by Nintedanib, Presented by Anna Y., Tufts University
B107: Fast and Scalable 1.8kb Gene Pool Assembly Platform for High-Throughput Screening Applications, Presented by Ketan P., Twist Bioscience
B108: Validation and Characterization of Antibodies Against Cancer Targets in >10,000 Tumor Tissue Samples from Nearly All Human Cancer Types, Presented by Ronald S., University Medical Center Hamburg-Eppendorf
B109: Biparatopic and Tetravalent Siglec-10 Antibodies Modulate Immune Cell Reactivity, Presented by Madison S., University of California, San Francisco
B110: Structure-Guided Engineering of a Conformation-Specific Antibody–Drug Conjugate for AML, Presented by Sujata W., University of California, San Francisco
B111: In Vivo Phage Display for the Discovery of Functional Tumor-Targeting and BBB-Crossing Antibodies, Presented by Frederico S., University of Lisbon
B112: Neurocytokine Shuttles for Efficient and Sustained CNS Immunomodulation, Presented by Wade K., University of Michigan
B113: Dual-Targeted Oligoshuttles Mediate Efficient Reduction of Neuronal Gene Expression After Peripheral Administration, Presented by YunxuanX., University of Michigan
B114: Protein Nanocages for Targeted Drug Delivery and Intracellular Cargo Release, Presented by Antonia M., University of Nottingham
B115: The Molecular Reach of Antibodies Determined by a Novel SPR-Based Assay Is Independent of Their Isotype, Presented by Luisa H., University of Oxford
B116: Compact Helical Bundle Scaffolds as High-Brightness NIR Probes for Fluorescence-Guided Surgery, Presented by Gabrielle H., University of Pennsylvania
B117: Identification and Biophysical Characterization of a Novel Domain-Swapped Camelid Antibody Specific for Fentanyl, Presented by Joseph G., University of Washington
B118: Mapping Polyclonal Antibody Epitopes in Native Environments Using Enrichment-Coupled HDX-MS, Presented by Clint V., University of Washington
B119: Novel Tools for Spatial Profiling of Protein Glycosylation in Cancer Biology, Presented by Erika L., Vector Laboratories
B120: Orthogonal Approaches to Aggregation Risk Monitoring and Screening for Complex Biologics, Presented by Nick P., Waters Corporation
B121: Broad-Reactive Monoclonal Antibodies Targeting Influenza H5Nx for Integrated Pandemic Readiness, Presented by Hyun P., Wonkwang University
B122: Next-Generation TCR-Like Antibodies with Improved Specificity Profiles, Presented by Oliver H., YUMAB GmbH
B123: Development and Characterization of a Rabbit Monoclonal Antibody for Specific Detection of Human IgG-Fc (YTE Mutation) Antibody, Presented by Haibin H., Yurogen Biosystems LLC
B124: Uniting Discovery Strategy and Engineering for the Best-in-Class Antibodies for ADC, Presented by Germanna R., Zymeworks
POSTER SESSION C: Thursday
C001: The Synthetic Epitope Atlas (SEPIA): Large-Scale Validation of De Novo Designed Epitopes to Accelerate Antibody Engineering, Presented by Joseph H., A-Alpha Bio
C002: Multi-Objective Engineering of Dual-Specific Antibodies Using AlphaBind, Presented by Leah H., A-Alpha Bio
C003: Beyond the PDB: The Synthetic Epitope Atlas for Training Antibody Design Models, Presented by Adrian L., A-Alpha Bio
C004: Opti-mAb®: A Novel scFv Format for Improved Therapies, Presented by Ionut D., AAX Biotech AB
C005: Targeting Inflammation and Fibrosis with CB2 Agonist Antibodies: Preclinical Efficacy in MASH and Neuropathy Models, Presented by Swastik S., Abalone Bio
C006: Automated Immunopeptidomics: High-Throughput MHC Peptide Profiling on the AssayMap Bravo Platform, Presented by Kazumi E., AbbVie, Inc.
C007: Multiomic Profiling of CAR-T Cells Identifies Drivers of Long-Term Persistence, Presented by Shih-Han W., Academia Sinica
C008: Bioconjugation Approaches for Personalized Endogenous T Cell Therapies, Presented by Caroline F., Albert Einstein College of Medicine
C009: Accurate Affinity Models for SH2 Domains from Peptide Binding Assays, Free-Energy Regression and Importance of Library Structure, Presented by Dejan G., Albert Einstein College of Medicine
C010: Influenza B Virus Bispecific Antibodies that Simultaneously Target Hemagglutinin and Neuraminidase, Presented by Sofia VE., Albert Einstein College of Medicine
C011: Addressing Challenges of Complex Molecules with a CMC Strategy Framework, Presented by Mark C., Altruist Biologics Suzhou Co., Ltd.
C012: AI-Guided Design of Functional Antibodies with Tailored Properties Against Challenging Targets, Presented by Ben H., Antiverse
C013: What Does the Liquid Brain See? From Coalescence Physics to Molecular Structure, Presented by Alex S., Apoha
C014: ARDiTox: Safer pHLA-Targeted Immunotherapies Through AI and Computational Immunology, Presented by Joanna MG., Ardigen S.A.
C015: AI-Driven De Novo Generation of Protein Binders, Presented by Matthew, Ardigen S.A.
C016: Single Domain Antibodies with Broad and Potent Activity Against Seasonal and Non-Seasonal Influenza A Viruses, Presented by Jessica J., AstraZeneca
C017: Identification of Logic Gated ADCs Using Combinatorial Screening, Presented by Kristof N., AstraZeneca
C018: Modular Generation of Multispecific Antibodies Using Protein Trans-Splicing, Presented by Jared S., AstraZeneca
C019: Utilizing Transposases for Expression of Complex Modalities and Precision Genome Engineering, Presented by Claes G., ATUM
C020: Linker Engineering of FGFR4-Targeted Exatecan Antibody–Drug Conjugates Enables Potent Antigen-Dependent Cytotoxicity and Improved Pharmacokinetic Performance, Presented by Mohammad R., Binghamton University, State University of New York
C021: Next-Generation Immunosuppressive ADCs: Targeted Delivery of Glucocorticoids to Activated Immune Cells for Chronic Inflammation, Presented by Aiman Y., Binghamton University, State University of New York
C022: BCG015: A First-in-Class Antibody-Drug Conjugate Targeting TM4SF5 for the Treatment of Hepatocellular Carcinoma, Presented by Icy N., Biocytogen
C023: GL-DisacLink® - A Promising Technology for Glycosite-Specific Conjugation, Presented by Lily Y., BioDlink
C024: Speed Counts While Quality Matters: A Fast-Track Approach to Bispecific Antibody Production, Presented by Huanyi Y., Biointron
C025: Pioneer Platform: A Novel Biotherapeutic Antibody Discovery Platform, Presented by Renee B., Bio-Rad Laboratories, Inc.
C026: Payload Specific Antibody Discovery for ADCs from HuCAL® Phage Display Antibody Library, Presented by Erika H., Bio-Rad Laboratories, Inc.
C027: High-Throughput, Automated Large-Scale Plasmid Purification: Eliminating Manual Bottlenecks in the Therapeutic Pipeline, Presented by Shadie N., Biotage
C028: High-Throughput Antibody Production Coupled with Rapid Charge and Size Characterization by icIEF and CE-SDS, Presented by Matt H., Bio-Techne
C029: Streamlined Cell Line Development of a CD28 Antibody: Integrating TcBuster™ and Ambr® Technology with Multi-Attribute Characterization, Presented by Srinivasa R., Bio-Techne
C030: FcRn Recycling Assay for Characterizing Antibody-Based Therapeutics, Presented by Elise I., Boehringer Ingelheim Pharmaceuticals, Inc.
C031: Engineering Towards the Utopia Point: Multi Objective Design of Biocatalyst Proteins, Presented by Yvett S., Boehringer Ingelheim Pharmaceuticals, Inc.
C032: Engineering a Small Molecule–Controlled Switch for CAR T Cell Regulation, Presented by Kerstin H., BOKU - University of Natural Resources and Life Sciences
C033: Engineering CAR T Cells to Specifically Target Ligand-Activated EGFR, Presented by Delia S., BOKU - University of Natural Resources and Life Sciences
C034: Evolution of Botulinum Neurotoxin Proteases To Induce Inflammatory Cell Death in Cancer Cells, Presented by Julia M., Broad Institute of MIT and Harvard
C035: Developing a Size-Based Microfluidic Electrophoresis Method to Determine the Drug-to-Antibody Ratio of Antibody-Drug Conjugates, Presented by Jenna R., Brown University
C036: High-Titer (>1.8 g/L) and Cost-Efficient Transient Expression in CHO-K1 Cells: Enabled by an Optimized Plug-and-Play System and PEl-Based Approach, Presented by Xiaoli L., Cellplus Biotechnology (Suzhou) Ltd.
C037: Synergy that Strengthens Safety: The Combined Application of Tissue Cross-Reactivity (TCR) and the Retrogenix® Cell Microarray Platform for More Comprehensive Safety Assessment, Presented by Laura R., Charles River Laboratories
C038: Pharmacophore-Guided Virtual Screening of Antibody Formats, Presented by Alain A., Chemical Computing Group
C039: Integrated Biologics Discovery Platform: Accelerating Complex Modality Development Through AI-Augmented Engineering and Comprehensive Characterization, Presented by Jin J., ChemPartner
C040: Novel Soluble Fc-Free CD19 Dimeric Protein for Specific, Sensitive and Broadly Applicable CD19 CAR-T Cell Detection by Flow Cytometry, Presented by Alyssa B., Conigen Bioscience
C041: Antibody and Therapeutics Discovery: Interrogating Large NGS Datasets, Presented by Monica W., Dotmatics
C042: Automated, High-Throughput Screening of Complex Biologics, Presented by Gary W., Protein Metrics by Dotmatics
C043: Mechanism-Driven Cell-Based Assays to Screen and Characterize Bi-Specific Antibodies, Presented by Gaurav A., Eurofins DiscoverX
C044: Integrated Evaluation of Payload-, Fc-, and Target-Mediated Mechanisms of ADCs Using Streamlined Complementary Platforms, Presented by Alpana P., Eurofins DiscoverX
C045: Screen, Select, Enhance: An Integrated Workflow for ADCC-Enhanced Antibody Development, Presented by Julia P., evitria AG
C046: Engineering EVOLVE-101: A CD180 Targeting T Cell Engager with Integrated CD2 Co-Stimulation, Presented by Xingyue A., EvolveImmune Therapeutics
C047: Expanding the Potential of Antibody Conjugates: AJICAP® Technology for Versatile DAR Control and Novel Modality Applications, Presented by Masahito K., Forge Biologics, a member of Ajinomoto Bio-Pharma Services
C048: Streamlining Biologic Workflows with Label-Free Quantitation and Binding Analysis, Presented by Vivienne L., Gator Bio
C049: A Digital Platform for the Development of Next-Generation Antibody Drug Conjugates (ADCs) and Other Antigen-Targeting Conjugates, Presented by Christopher M., Genedata AG
C050: Establishing Reliable PK Evaluation Criteria: A Validated Transcytosis Assay for Monoclonal Antibodies and Comparative Study with SCID PK, Presented by Chang L., Genentech
C051: GenSci155, a Novel Long-Acting IGF-1 Peptide Analog for the Treatment of sPIGFD, BPD and AIS Diseases, Presented by Feifei R., GeneScience Pharmaceutical Co., Ltd.
C052: Leveraging High-Throughput Platforms for the Discovery of Bispecific Antibodies, Presented by Crystal R., GENEWIZ from Azenta Life Sciences
C053: A Novel AI/ML Approach to Codon Optimization for Enhanced Antibody Expression, Presented by Andrew T., GENEWIZ from Azenta Life Sciences
C054: Strategic Use of Advanced Technologies and Multiple Host Species to Rapidly Generate Cost-Effective Antibody Candidates, Presented by Matt W., Genovac Antibody Discovery LLC
C055: Accelerating AI-Driven Discovery with an Integrated Cell-Free Sequence-to-Data Platform, Presented by YC L., GenScript
C056: Improving Scalable, High-Throughput Affinity Protein Purification Workflows with Magnetic Beads-Based Automated Solutions, Presented by Luciana R., GenScript
C057: Leveraging Prior Knowledge: Potency Assay Development for a Multi-Paratopic Biologic, Presented by AaronC., Gilead Sciences
C058: Precision Brain Shuttle Platform Tailored to Breast Cancer Brain Metastasis, Presented by Yifei L., Harvard University
C059: Early Antibody Developability Package — Reducing Manufacturing & Clinical Risks, Presented by Lauri P., Icosagen Cell Factory OÜ
C060: Engineering a GAS6 Fusion Protein (GAIA) enabling Non-Inflammatory Amyloid-ß Clearance for Safer Alzheimer’s Disease Therapy, Presented by Jinju P. & Seul Gi K., Illimis Therapeutics
C061: Enhancing Antibody Developability Prediction with Hybrid Sequence–Structure Modeling, Presented by Stefania E., Insilico medicine
C062: High-Throughput SPR Workflows for Antibody Characterization at IPI: Kinetics and Epitope Binning, Presented by Aditi K., Institute for Protein Innovation
C063: IPIAbDev: Interpretable Machine Learning for Antibody Developability Prediction and Discovery, Presented by Hoan N., Institute for Protein Innovation
C064: Enabling Rapid Bispecific Antibody Discovery with Invenra’s B-Body Platform, Presented by Hongbo C., Invenra
C065: Mechanistic Insights into the Immunomodulatory Effects of a Potentiating Antibody Targeting the Interleukin-7 Cytokine, Presented by Emily A., Johns Hopkins University
C066: Engineered Multi-Paratopic Antibody-Drug Conjugates Target and Destroy Tumor Cells Through Multiple Modalities, Presented by Lauren C., Johns Hopkins University
C067: Targeted Antibody/Cytokine Fusion Protein Antagonists to Overcome T[reg]-Mediated Immunosuppression in Tumors, Presented by Luke T., Johns Hopkins University
C068: Accelerated Production of Biotinylated Protein Reagents Through Coexpression with Biotin Ligase, Presented by Emma A., Kite Pharma, a Gilead Company
C069: Programmable DNA Nanostructures for Spatial Organization and Delivery of Growth Factor–Mimicking Peptides, Presented by Bo KyungC., Korea Institute of Science and Technology
C070: Unlocking Therapeutic Potential: Why Site-Specific Hybridization Is Essential Over Non-Specific Peptide Adsorption on DNA Origami, Presented by Youngjin C., Korea Institute of Science and Technology
C071: Comprehensive Glycosylation Analysis to Meet Regulatory Requirements: Full N-Glycan Characterisation and Quantitation of Sialic Acids, Presented by Radoslaw K., Ludger Ltd.
C072: Improving Protein Stability Through Deep Learning Method: The MatwingsVenus™ Platform, Presented by Song L., Matwings Technology
C073: Advancing the Discovery and Development of Biologics and Next-Generation Immunotherapies through Innovative Expression and Screening Techniques, Presented by Nitin K., MaxCyte
C074: ML-Guided Design of GLP-2R Agonist Antibodies with Improved In Vivo Activity Supporting Extended Dosing, Presented by Bharat M., Metaphore Biotechnologies
C075: Beyond the Impact: Antibody Sequences as Predictive Biomarkers for Pediatric Traumatic Brain Injury, Presented by Annie N., Michigan State University
C076: Rational Design of Protein A Variants Using AI-Driven In Silico Modeling for Enhanced Affinity Chromatography Performance, Presented by Christopher P., MilliporeSigma
C077: Discovery and Preclinical Development of a PD-1/IL-2v Bispecific Antibody Cytokine Fusion Protein with AI-Powered MoleculeOS(MOS) Technology, Presented by Lillian M., Molecule Mind
C078: Synergistic Effects of Co-Solutes and Heat on the Physical Stability of GLP-1am, Presented by Bridget M., NanoTemper Technologies
C079: Engineering Amide Synthetases for Sequenced Oligoamide Synthesis, Presented by Liangyu Q., Oak Ridge National Laboratory
C080: Empowering the Efficient Discovery of Ultralong CDRH3 Antibodies with High-Throughput xPloration® Workflows, Presented by Colin W., OmniAb
C081: Systematic Developability Profiling of a Large Panel of Bispecifics Derived From Clinical Stage Antibodies, Presented by Aris P., PAIA Biotech GmbH
C082: A High-Throughput Nanovial Workflow for Functional Validation of Immune Cell–Target Cell Interactions, Presented by Joe D., Partillion Bioscience
C083: Adaptive Quantum Ansatz for Tetrahedral-Lattice Protein Folding, Presented by Frederic C., peaccel
C084: Profiling ADC In Vitro Catabolism: A Systemic Approach from Incubation to Identification, Presented by Jackson A., Pharmaron
C085: Comprehensive In Vitro Mechanistic Characterization of Dato-DXd, a Trop2 Directed ADC, Presented by Zhaoyang D., Pharmaron
C086: In Vitro Assessment of Potential Hematotoxicity of ADC Drugs, Presented by Medha T., Pharmaron
C087: Increase Antibody Titers in Flasks with Automated Continuous Feeding, Presented by Toke F., PROAnalytics LLC & atSpiro
C088: Bioluminescent Assays for Antibody-Drug Conjugate Development: Internalization and Bystander Killing Functions, Presented by Andrew Z., Promega Corporation
C089: MAM-Easy: A Standardized Kit-Based Workflow for Reproducible Biotherapeutic Quality Monitoring, Presented by Tyler S. & John W., ProtiFi
C090: Single-Molecule Protein Sequencing for the Characterization of Proteins, Purification Impurities, and Binding Kinetics, Presented by David S., Quantum-Si, Inc.
C091: Conversion of Polyclonal Anti-Idiotypes into Characterized Recombinant Antibodies, Presented by Thierry L., Rapid Novor
C092: Combining icIEF-Fractionation and Mass Photometry to Provide Insights on Bispecific Antibody and Biosimilar Development, Presented by Gael N., Refeyn, Inc.
C093: LocIn: A Targeted Integration System for the Efficient Creation of Isogenic Mammalian Cell Lines, Presented by Lewis C., RoukenBio
C094: Early Developability Assessment (EDA) as a Data Driven Precursor for Robust AI/ML Model Training Pipelines, Presented by Andrzej D., Selvita S.A.
C095: Impact of Fc Engineering on CAR-T Directing mAbs: Derisking Antigen-Specific FcR Binding and Consequent Effector Function, Presented by Amanda C., SeromYx Systems, Inc.
C096: Design of Bispecific Antibody Fc Region Employing a Shark-Human Chimeric and Asymmetric Format, Presented by Ryota M., Taiho Pharmaceutical Co., Ltd.
C097: Light Chain Charge Mutations and Bulk Pool Scouting allow Selection of Minipools expressing 1:1 Bispecifics with Exceptional Product Quality, Presented by Megha W., Takeda Pharmaceuticals
C098: Driving AOC and ADC Success with Precision Bioconjugation and Trafficking Insights, Presented by Chris L., Thermo Fisher Scientific
C099: Automating the Expi293™ PRO Expression System for High Throughput Protein Expression, Presented by Matt M., Thermo Fisher Scientific
C100: High-Throughput Media and Feed Screening, Presented by Matthew S., Thermo Fisher Scientific
C101: 21-Fold Increase in Plasmid Production Yield Compared to Traditional Methods, Presented by Jordan L., Thomson Instrument Company
C102: Glycopeptide Phage Display for the Discovery of New Treatments Against Pathogenic Lectins, Presented by Chris M., University College London
C103: Computational Modeling of Antibody-Drug Conjugates (ADCs) for HIV Treatment, Presented by Jiakun G., University of Michigan
C104: StrucNS Reveals Interaction-Weighted Network Topology as the Driving Predictor of Absolute Stability of Natural and De Novo Proteins, Presented by Archita M., University of Minnesota, Twin Cities
C105: Engineering Isoform-Specific Miniprotein Binders to the Fetal Form of the Insulin Receptor, Presented by Melissa W., University of Minnesota, Twin Cities
C106: Multimeric Designed Single Chain Antibody (MeDuSA): A Nanobody Fc-Based Platform for Tri-Specific Antibodies, Presented by Charlie J., University of Texas, Austin
C107: Integrating Machine Learning with MDS to Improve PancACe, Presented by Austin A., University of Utah
C108: De Novo Design and Engineering of Sequence-Specific Proteases Using Deep Learning, Presented by Anqi C., University of Washington
C109: Design, Stabilize, Design: Using a Variety of Machine Learning Tools to Create De Novo TLRs and Their Antibodies, Presented by Cameron C., University of Washington
C110: Computational Design of Bifaceted Protein Nanomaterials With Tailorable Properties, Presented by Sanela R., University of Washington
C111: Comparing Potential Bispecific Formats Comprising of Trastuzumab and a Humanized OKT3, Presented by Catherine B., Vector Laboratories
C112: Synergistic Strategies for Biologic Design and Functionalization Using Modular Chemistry and Antibody Engineering, Presented by Matt G., Vector Laboratories
C113: Bi-Specific Antibody Generation - In House Study by Controlled Fab-Arm Exchange (cFAE), Presented by Timothy D., Viva Biotech
C114: AI-MPRO: Tackling Challenging Targets with De Novo Miniproteins, Presented by Gabor O., VRG Therapeutics Ltd.
C115: Application of Glatiramoid Polypeptides in Cancer Immunotherapy, Presented by Huan G., Washington University in Saint Louis
C116: In Silico Optimisation of Inhibitor Protein with Improved Thermostability and Expression, Presented by Mark A. & Campbell M., Watchmaker Genomics
C117: Comprehensive LC-MS Analytical Assays for Antibody-Oligonucleotide Conjugate (AOC) and siRNA Linker-Payload Characterization, Presented by Samuel S., Waters Corporation
C118: Enabling Active Learning-Guided Protein Engineering Through Rapid Variant DNA Assembly, Presented by Kaveh D., Way Biosolutions
C119: Computational Design of Synthetic Antibody Repertoires for Enhanced Developability, Presented by Rebecca W., Weizmann Institute
C120: In-Depth SPR Characterization Throughout Biologics Drug Discovery and Development, Presented by Mingming S., WuXi Biologics
C121: Accelerating Bioconjugates Discovery via Optimized Linker-Payload Customization Platform at WuXi XDC, Presented by Rachana O., WuXi XDC
C122: Driving Dual-Payload ADC (dp-ADC) Development with Proprietary WuXiDARx™, X-LinC, and WuXiTecan-2, Presented by Rui W., WuXi XDC
C123: Integrated Bioconjugate Discovery Services at WuXi XDC, Presented by Gang Y., WuXi XDC
C124: Fluorosulfuryl Derivatives of Established Drugs for Imaging Radiopharmaceuticals, Presented by Joong-Hyun C., Yonsei University
ADDITIONAL VIRTUAL POSTERS
V1: The Application of Nanodisc Technology Platform to Develop Therapeutic mAbs for Multi-Pass Transmembrane Protein Targets, Presented by Donghui M., DIMA Biotechnology Ltd.
V2: Utilization of Chelators for Analyzing Oxidative Degradation of Antibody Therapeutics, Presented by Poulami M., Eli Lilly and Company
V3: Developing a Cell-Based Potency Assay with the In-Cell Western Assay, Presented by Jessica Z., LICORbio
V4: High-Throughput Protein Stability Screens with Aunty, Presented by Andre M., Unchained Labs
V5: A Structural Platform for Molecular Glues and Protacs Discovery: SPR Fragment Screening and Crystallography Hit Validation With CRBN[midi], Presented by James F., Sygnature Discovery
V6: Dual Plasmid Engineering Enhanced Soluble Production of Bioactive Recombinant Human GM-CSF in E. coli, Presented by Maedeh M., Royan Institute